English
Back
Open Account
2026 IPO bonanza! Over 90% of new stocks rose on their debut
富途资讯
joined discussion · Jun 5 08:44

IPO Pricing | 'Hong Kong beauty and health retail chain' Lung Fung Group listed today, receiving 664.92 times subscription, priced at HK$5.18 per share

Futu News, June 5: $LUNG FUNG GROUP (02290.HK)$ The allotment results have been announced, with a price of HK$5.18 per share, issuing a total of 125 million shares, with each board lot comprising 500 shares. The shares officially listed today.
During the public offering stage, Lung Fung Group received 664.92 times subscription. The final number of shares allocated to the public offering was 12.5 million shares, representing approximately 10% of the total offering. Approximately 133,200 valid applications were received in total, with about 16,359 applications processed. The approximate percentage of applicants who applied for one board lot and were successfully allotted shares was 5% of the total number of shares applied for.
Additionally, during the international placement stage, Lung Fung Group received 3.18 times subscription. The final number of shares allocated to the international offering was 113 million shares, equivalent to 90% of the total offering. Futu News has compiled the relevant data in the table below:
Futu News, June 5: $LUNG FUNG GROUP (02290.HK)$ The allotment results have been announced, with a price of HK$5.18 per share, issuing a total of 125 million shares, with each board lot comprising 500 shares. The shares officially listed today. During the public offering stage, Lung Fung Group received 664.92 times subscription. The final number of shares allocated to the public offering was 12.5 million shares, representing approximately 10% of the total offering. Approximately 133,200 valid applications were received in total, with about 16,359 applications processed. The approximate percentage of applicants who applied for one board lot and were successfully allotted shares was 5% of the total number of shares applied for. Additionally, during the international placement stage, Lung Fung Group received 3.18 times subscription. The final number of shares allocated to the international offering was 113 million shares, equivalent to 90% of the total offering. Futu News has compiled the relevant data in the table below: Company Overview Lung Fung Group is a leading Hong Kong-based retail chain operating under the 'Lung Fung' brand, specializing in cosmetics, health supplements, and pharmaceutical products. As of the latest practicable date, the company operates 31 retail stores in Hong Kong and multiple online sales platforms, focusing on delivering a wide selection of high-value products to customers. With over 30 years of experience, the company has developed a strong capability to effectively identify and respond to consumer demand in the local retail market, establishing itself as a one-stop supplier of cosmetics, health supplements, and pharmaceuticals. The company possesses strong supply chain procurement capabilities, as of 2025...
Futu News, June 5: $LUNG FUNG GROUP (02290.HK)$ The allotment results have been announced, with a price of HK$5.18 per share, issuing a total of 125 million shares, with each board lot comprising 500 shares. The shares officially listed today. During the public offering stage, Lung Fung Group received 664.92 times subscription. The final number of shares allocated to the public offering was 12.5 million shares, representing approximately 10% of the total offering. Approximately 133,200 valid applications were received in total, with about 16,359 applications processed. The approximate percentage of applicants who applied for one board lot and were successfully allotted shares was 5% of the total number of shares applied for. Additionally, during the international placement stage, Lung Fung Group received 3.18 times subscription. The final number of shares allocated to the international offering was 113 million shares, equivalent to 90% of the total offering. Futu News has compiled the relevant data in the table below: Company Overview Lung Fung Group is a leading Hong Kong-based retail chain operating under the 'Lung Fung' brand, specializing in cosmetics, health supplements, and pharmaceutical products. As of the latest practicable date, the company operates 31 retail stores in Hong Kong and multiple online sales platforms, focusing on delivering a wide selection of high-value products to customers. With over 30 years of experience, the company has developed a strong capability to effectively identify and respond to consumer demand in the local retail market, establishing itself as a one-stop supplier of cosmetics, health supplements, and pharmaceuticals. The company possesses strong supply chain procurement capabilities, as of 2025...
Company Overview
Lung Fung Group is a leading Hong Kong-based retail chain operating under the 'Lung Fung' brand, specializing in cosmetics, health supplements, and pharmaceutical products. As of the latest practicable date, the company operates 31 retail stores in Hong Kong and multiple online sales platforms, focusing on delivering a wide selection of high-value products to customers. With over 30 years of experience, the company has developed a strong capability to effectively identify and respond to consumer demand in the local retail market, establishing itself as a one-stop supplier of cosmetics, health supplements, and pharmaceuticals.
The company possesses robust supply chain procurement capabilities, sourcing from over 600 suppliers—including international brand manufacturers and authorized distributors—as of November 30, 2025, ensuring stable and timely product availability. In each of the fiscal years 2023, 2024, and 2025, three of the company’s top five suppliers had maintained business relationships exceeding 15 years.
Financial Summary
For the fiscal years 2023, 2024, and 2025, Lung Fung Group reported total revenues of HK$10,940 million, HK$20,207 million, and HK$24,605 million, respectively, representing a compound annual growth rate of 50.0% over the three-year period. The company recorded a loss of HK$271 million in fiscal year 2023, followed by net profits of HK$1,445 million and HK$1,704 million in fiscal years 2024 and 2025, respectively, reflecting a 17.9% increase over the two-year period.
Futu News, June 5: $LUNG FUNG GROUP (02290.HK)$ The allotment results have been announced, with a price of HK$5.18 per share, issuing a total of 125 million shares, with each board lot comprising 500 shares. The shares officially listed today. During the public offering stage, Lung Fung Group received 664.92 times subscription. The final number of shares allocated to the public offering was 12.5 million shares, representing approximately 10% of the total offering. Approximately 133,200 valid applications were received in total, with about 16,359 applications processed. The approximate percentage of applicants who applied for one board lot and were successfully allotted shares was 5% of the total number of shares applied for. Additionally, during the international placement stage, Lung Fung Group received 3.18 times subscription. The final number of shares allocated to the international offering was 113 million shares, equivalent to 90% of the total offering. Futu News has compiled the relevant data in the table below: Company Overview Lung Fung Group is a leading Hong Kong-based retail chain operating under the 'Lung Fung' brand, specializing in cosmetics, health supplements, and pharmaceutical products. As of the latest practicable date, the company operates 31 retail stores in Hong Kong and multiple online sales platforms, focusing on delivering a wide selection of high-value products to customers. With over 30 years of experience, the company has developed a strong capability to effectively identify and respond to consumer demand in the local retail market, establishing itself as a one-stop supplier of cosmetics, health supplements, and pharmaceuticals. The company possesses strong supply chain procurement capabilities, as of 2025...
Use of Proceeds
Regarding the use of proceeds, Lung Fung Group expects net proceeds from the global offering to amount to approximately HK$600 million (based on the offer price of HK$5.18 per share). According to the prospectus, Lung Fung Group intends to allocate the funds raised from the global offering for the following purposes:
Approximately 36.6% is expected to be used to expand, enhance, and optimize the company’s physical and online sales networks; approximately 3.5% is expected to be allocated to brand management and marketing activities to enhance the group’s public recognition and the effectiveness of its marketing campaigns; approximately 3.5% is expected to be used to strengthen the company’s supply chain capabilities by expanding and upgrading its existing procurement office and warehouse in Japan, as well as its warehouse in Korea; and approximately 11.4% is expected to be used to upgrade and improve the company’s information technology systems.
Approximately 20% is expected to be used to repay the company’s outstanding borrowings; approximately 15% is expected to be allocated toward pursuing selective strategic investments and acquisition opportunities, as well as further developing strategic partnerships to expand the company’s business scale and geographic reach; and approximately 10% is expected to be used as general working capital for the group.
The golden season for new stock subscriptions has arrived! Use Futu for new stock subscriptions—zero interest, zero handling fees, and zero cash subscription. Participants now have the chance to have their new stock subscription fees waived for a year.Come and experience it now >>
Futu News, June 5: $LUNG FUNG GROUP (02290.HK)$ The allotment results have been announced, with a price of HK$5.18 per share, issuing a total of 125 million shares, with each board lot comprising 500 shares. The shares officially listed today. During the public offering stage, Lung Fung Group received 664.92 times subscription. The final number of shares allocated to the public offering was 12.5 million shares, representing approximately 10% of the total offering. Approximately 133,200 valid applications were received in total, with about 16,359 applications processed. The approximate percentage of applicants who applied for one board lot and were successfully allotted shares was 5% of the total number of shares applied for. Additionally, during the international placement stage, Lung Fung Group received 3.18 times subscription. The final number of shares allocated to the international offering was 113 million shares, equivalent to 90% of the total offering. Futu News has compiled the relevant data in the table below: Company Overview Lung Fung Group is a leading Hong Kong-based retail chain operating under the 'Lung Fung' brand, specializing in cosmetics, health supplements, and pharmaceutical products. As of the latest practicable date, the company operates 31 retail stores in Hong Kong and multiple online sales platforms, focusing on delivering a wide selection of high-value products to customers. With over 30 years of experience, the company has developed a strong capability to effectively identify and respond to consumer demand in the local retail market, establishing itself as a one-stop supplier of cosmetics, health supplements, and pharmaceuticals. The company possesses strong supply chain procurement capabilities, as of 2025...
Editor/Joe
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
Thumbs Up
5
Heart
1
174K Views
Report
Comments
Write a Comment...
6
52